ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

HypERlnc attenuates angiotensin II-induced cardiomyocyte hypertrophy via promoting SIRT1 SUMOylation-mediated activation of PGC-1α/PPARα pathway in AC16 cells

Yue, Lijuan; Sheng, Siqi; Yuan, Meng; Lu, Jing; Li, Tianyu*; Shi, Yuanqi*; Dong, Zengxiang*哈尔滨医科大学; 1
CELL BIOLOGY INTERNATIONAL2023-6DOI: 10.1002/cbin.12001
9阅读
引用收藏
分享

摘要

Cardiac hypertrophy is a well-established risk factor for cardiovascular mortality worldwide. According to a recent study, hypoxia-induced endoplasmic reticulum stress regulating long noncoding RNA (HypERlnc) is significantly reduced in the left ventricular myocardium of heart failure (HF) patients compared with healthy controls. However, the effect of HypERlnc on hypertrophy is unclear. In this study, the expression level of HypERlnc in serum of patients with chronic HF was analyzed. Moreover, the cardioprotective effect and mechanism of HypERlnc against cardiomyocyte hypertrophy were explored. Here, the level of HypERlnc expression was reduced in serum of patients with HF and in Angiotensin II (Ang II)-stimulated AC16 cells. HypERlnc overexpression could reduce cell size and inhibit expression of hypertrophy genes (ANP, BNP, and beta-MHC) in the Ang II-induced cardiomyocyte hypertrophy. Meanwhile, HypERlnc could improve the Ang II-induced energy metabolism dysfunction and mitochondrial damage via upregulating PGC-1 alpha/PPAR alpha signaling pathway. Furthermore, it is found that SIRT1 SUMOylation mediated the HypERlnc-induced inhibition of cardiomyocyte hypertrophy and the improvement of energy metabolism. Taken together, this study suggests that HypERlnc suppresses cardiomyocyte hypertrophy and energy metabolism dysfunction via enhancing SUMOylation of SIRT1 protein. HypERlnc is a potential novel molecular target for preventing and treating pathological cardiac hypertrophy.

学科与关键词

关键词
cardiac hypertrophyHypERlnclncRNASIRT1SUMO1
相关
加载中…
  • SUMOylation of SIRT1 activating PGC-1?/PPAR? pathway mediates the protective effect of LncRNA-MHRT in cardiac hypertrophy
    Liu, Ming-yu; Yue, Li-juan; Luo, Ying-chun; Lu, Jing; Wu, Guo-dong; Sheng, Si-qi; Shi, Yuan-qi*; Dong, Zeng-xiang*European Journal of Pharmacology, 2022, 930: 175155.被引 6
  • Long non-coding RNA KCND1 protects hearts from hypertrophy by targeting YBX1
    Yang, Rui; Li, Liangliang; Hou, Yumeng; Li, Yingnan; Zhang, Jing; Yang, Na; Zhang, Yuhan; Ji, Weihang; Yu, Tong; Lv, Lifang; Liang, Haihai; Li, Xuelian; Li, Tianyu*; Shan, Hongli*Cell Death & Disease, 2023, 14(5): 344.被引 2
  • Neutrophil-like cell membrane-coated siRNA of lncRNA AABR07017145.1 therapy for cardiac hypertrophy via inhibiting ferroptosis of CMECs
    Shi, Pilong; Li, Minghui; Song, Chao; Qi, Hanping; Ba, Lina; Cao, Yonggang; Zhang, Meitian; Xie, Yawen; Ren, Jing; Wu, Jiabi; Ren, Ping; Sun, Hongli*Molecular Therapy-Nucleic Acids, 2022, 27: 16-36.被引 20
查看全部 →

发表信息

论文状态
公开发表
期刊
CELL BIOLOGY INTERNATIONAL
发表日期
2023-06
卷期
第 47 卷, 第 6 期
页码
1068-1080
DOI
10.1002/cbin.12001
语言
ENGLISH
成果收录
SCIE
资助标注
National Natural Science Foundation of China [81870169, 82170270, 81700303, 81900225]; Research Project of the First Affiliated Hospital of Harbin Medical University [2021J01, 2021Y09]

作者

  • Y

    Yue, Lijuan (第一作者)

    harbin med univ

  • S

    Sheng, Siqi

    1 · harbin med univ

查看全部 7 位作者收起作者
  • Y

    Yuan, Meng

    harbin med univ

  • L

    Lu, Jing

    harbin med univ

  • L

    Li, Tianyu (通讯)

    harbin med univ

  • S

    Shi, Yuanqi (通讯)

    1 · harbin med univ

  • D

    Dong, Zengxiang (通讯)

    1 · harbin med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417